Document Detail

Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy.
MedLine Citation:
PMID:  19707467     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: Recurrent fetal loss (RPL) is one of the most common cause of sterility. Several studies identified thrombophilia as the principal cause of recurrent pregnancy loss. However, reported studies often do not evaluate other causes of miscarriages in their inclusion and exclusion criteria. So the aim of our study was to investigate the role of inherited thrombophilia in patients with RPL and without other causes of RPL.
PATIENTS AND METHODS: Patients with 2 or more first trimester abortion or with 1 or more late pregnancy loss were considered for this study. In order to evaluate the causes of RPL we looked for chromosomal, endocrine, chronic inflammatory, and infectious alterations. 90 patients affected by unexplained RPL were enrolled and tested for hemostatic alterations. These women were tested for inherited and/or acquired thrombophilia by MTHFR C677T gene polymorphism, factor V Leiden gene polymorphism, PTHRA20210G gene polymorphism, protein S deficiency, protein C deficiency, antithrombin III deficiency, lupus anticoagulant, and anticardiolipin antibodies Ig G and Ig M.
RESULTS: Acquired and/or inherited thrombophilia are strongly associated with RPL when other common causes of miscarriage were excluded. 78% of tested women showed hemostatic abnormalities. Several women with combined thrombophilic defects were also identified by our data.
CONCLUSION: After a thorough evaluation of other causes of miscarriage women affected by RPL should be tested for thrombophilia. Our data demonstrated 78% of women with one or combined thrombophilic conditions. Differences with previous studies should be related to difference in the inclusion and exclusion criteria and ethnic background. Because these patients often also show a hypercoagulable state, it an antithrombotic treatment before and during pregnancy may improve their clinical outcome (ie, secondary prevention of miscarriage and primary thromboprophylaxis).
Maristella D'Uva; Pierpaolo Di Micco; Ida Strina; Antonio Ranieri; Carlo Alviggi; Antonio Mollo; Francesca Fabozzi; Lucia Cacciapuoti; Maria Teresa Scotto di Frega; Mariateresa Iannuzzo; Giuseppe De Placido
Related Documents :
21087767 - Associations between maternal characteristics and pregnancy-related stress among low-ri...
21482367 - Simultaneous use of mifepristone and misoprostol for early pregnancy termination.
21322747 - Trophoblast apoptosis in human term placentas from pregnancies complicated with idiopat...
6362087 - Development of a direct enzyme immunoassay of milk progesterone and its application to ...
15143117 - Maternal fish intake in late pregnancy and the frequency of low birth weight and intrau...
4077767 - Follicular development during the prepuberal period of different morphological types of...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Biologics : targets & therapy     Volume:  2     ISSN:  1177-5475     ISO Abbreviation:  Biologics     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2009-08-26     Completed Date:  2011-07-14     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  101321511     Medline TA:  Biologics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  897-902     Citation Subset:  -    
Dipartimento Universitario di Scienze Ostetriche Ginecologiche e Medicina della Riproduzione, Area Funzionale di Medicina della Riproduzione ed Endoscopia Ginecologica, Università degli Studi di Napoli Federico II, via Pansini 5 Building 9, 80131, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agen...
Next Document:  Use of a decoy peptide to purify p21 activated kinase-1 in cardiac muscle and identification of cera...